224 related articles for article (PubMed ID: 11431341)
1. Inhibition of fibroblast growth factor-2-induced vascular tumor formation by the acyclic nucleoside phosphonate cidofovir.
Liekens S; Neyts J; De Clercq E; Verbeken E; Ribatti D; Presta M
Cancer Res; 2001 Jul; 61(13):5057-64. PubMed ID: 11431341
[TBL] [Abstract][Full Text] [Related]
2. The nucleotide analog cidofovir suppresses basic fibroblast growth factor (FGF2) expression and signaling and induces apoptosis in FGF2-overexpressing endothelial cells.
Liekens S; Gijsbers S; Vanstreels E; Daelemans D; De Clercq E; Hatse S
Mol Pharmacol; 2007 Mar; 71(3):695-703. PubMed ID: 17158200
[TBL] [Abstract][Full Text] [Related]
3. The broad-spectrum anti-DNA virus agent cidofovir inhibits lung metastasis of virus-independent, FGF2-driven tumors.
Liekens S; Noppen S; Gijsbers S; Sienaert R; Ronca R; Tobia C; Presta M
Oncotarget; 2015 Mar; 6(7):4633-48. PubMed ID: 25609197
[TBL] [Abstract][Full Text] [Related]
4. Potent inhibition of hemangiosarcoma development in mice by cidofovir.
Liekens S; Verbeken E; De Clercq E; Neyts J
Int J Cancer; 2001 Apr; 92(2):161-7. PubMed ID: 11291040
[TBL] [Abstract][Full Text] [Related]
5. Alterations of blood vessel development by endothelial cells overexpressing fibroblast growth factor-2.
Ribatti D; Gualandris A; Belleri M; Massardi L; Nico B; Rusnati M; Dell'Era P; Vacca A; Roncali L; Presta M
J Pathol; 1999 Dec; 189(4):590-9. PubMed ID: 10629563
[TBL] [Abstract][Full Text] [Related]
6. Antiviral agent cidofovir decreases Epstein-Barr virus (EBV) oncoproteins and enhances the radiosensitivity in EBV-related malignancies.
Abdulkarim B; Sabri S; Zelenika D; Deutsch E; Frascogna V; Klijanienko J; Vainchenker W; Joab I; Bourhis J
Oncogene; 2003 Apr; 22(15):2260-71. PubMed ID: 12700662
[TBL] [Abstract][Full Text] [Related]
7. Potent inhibition of hemangioma formation in rats by the acyclic nucleoside phosphonate analogue cidofovir.
Liekens S; Andrei G; Vandeputte M; De Clercq E; Neyts J
Cancer Res; 1998 Jun; 58(12):2562-7. PubMed ID: 9635579
[TBL] [Abstract][Full Text] [Related]
8. The role of growth factors, angiogenic enzymes and apoptosis in neovascularization and tumor growth-collected publications.
Liekens S
Verh K Acad Geneeskd Belg; 2002; 64(3):197-224. PubMed ID: 12238243
[TBL] [Abstract][Full Text] [Related]
9. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
10. Prevention and inhibition of nasopharyngeal carcinoma growth by antiviral phosphonated nucleoside analogs.
Murono S; Raab-Traub N; Pagano JS
Cancer Res; 2001 Nov; 61(21):7875-7. PubMed ID: 11691806
[TBL] [Abstract][Full Text] [Related]
11. Modulation of tumor angiogenesis by conditional expression of fibroblast growth factor-2 affects early but not established tumors.
Giavazzi R; Giuliani R; Coltrini D; Bani MR; Ferri C; Sennino B; Tosatti MP; Stoppacciaro A; Presta M
Cancer Res; 2001 Jan; 61(1):309-17. PubMed ID: 11196179
[TBL] [Abstract][Full Text] [Related]
12. Purine analogue 6-methylmercaptopurine riboside inhibits early and late phases of the angiogenesis process.
Presta M; Rusnati M; Belleri M; Morbidelli L; Ziche M; Ribatti D
Cancer Res; 1999 May; 59(10):2417-24. PubMed ID: 10344752
[TBL] [Abstract][Full Text] [Related]
13. The chemopreventive agent oltipraz possesses potent antiangiogenic activity in vitro, ex vivo, and in vivo and inhibits tumor xenograft growth.
Ruggeri BA; Robinson C; Angeles T; Wilkinson J; Clapper ML
Clin Cancer Res; 2002 Jan; 8(1):267-74. PubMed ID: 11801568
[TBL] [Abstract][Full Text] [Related]
14. Paracrine and autocrine effects of fibroblast growth factor-4 in endothelial cells.
Dell'Era P; Belleri M; Stabile H; Massardi ML; Ribatti D; Presta M
Oncogene; 2001 May; 20(21):2655-63. PubMed ID: 11420677
[TBL] [Abstract][Full Text] [Related]
15. Inhibiting effects of cidofovir (HPMPC) on the growth of the human cervical carcinoma (SiHa) xenografts in athymic nude mice.
Andrei G; Snoeck R; Piette J; Delvenne P; De Clercq E
Oncol Res; 1998; 10(10):533-9. PubMed ID: 10338156
[TBL] [Abstract][Full Text] [Related]
16. Antiproliferative effects of acyclic nucleoside phosphonates on human papillomavirus (HPV)-harboring cell lines compared with HPV-negative cell lines.
Andrei G; Snoeck R; Piette J; Delvenne P; De Clercq E
Oncol Res; 1998; 10(10):523-31. PubMed ID: 10338155
[TBL] [Abstract][Full Text] [Related]
17. Antiviral agent Cidofovir restores p53 function and enhances the radiosensitivity in HPV-associated cancers.
Abdulkarim B; Sabri S; Deutsch E; Chagraoui H; Maggiorella L; Thierry J; Eschwege F; Vainchenker W; Chouaïb S; Bourhis J
Oncogene; 2002 Apr; 21(15):2334-46. PubMed ID: 11948417
[TBL] [Abstract][Full Text] [Related]
18. Multiple roles for platelet GPIIb/IIIa and alphavbeta3 integrins in tumor growth, angiogenesis, and metastasis.
Trikha M; Zhou Z; Timar J; Raso E; Kennel M; Emmell E; Nakada MT
Cancer Res; 2002 May; 62(10):2824-33. PubMed ID: 12019160
[TBL] [Abstract][Full Text] [Related]
19. New inhibitors of cytomegalovirus replication: in vitro evaluation, mechanism of action, and in vivo activity.
Neyts J; De Clercq E
Verh K Acad Geneeskd Belg; 1994; 56(6):561-92. PubMed ID: 7892749
[TBL] [Abstract][Full Text] [Related]
20. Ribonucleotide reductase inhibitors enhance cidofovir-induced apoptosis in EBV-positive nasopharyngeal carcinoma xenografts.
Wakisaka N; Yoshizaki T; Raab-Traub N; Pagano JS
Int J Cancer; 2005 Sep; 116(4):640-5. PubMed ID: 15818619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
